Neuroprotection is the cross-cutting theme that ties two otherwise distant peptide stories together: the metabolic incretin class repurposed for cognitive decline, and the small targeted peptides designed from scratch to home to injured brain tissue.
On the GLP-1 side, the AAN 2026 Living Review covered on this site reported a 20–35% reduction in dementia incidence across 2 million-plus diabetics on GLP-1 agonists, and NeurologyLive's repositioning piece mapped the path through Alzheimer's, Parkinson's, and adjacent indications. The EVOKE and EVOKE+ Phase 3 results in Alzheimer's were negative, but real-world data and earlier-phase liraglutide work continue to feed the case.
On the targeted-peptide side, Aivocode's CAQK tetrapeptide — published in EMBO Molecular Medicine and developed in collaboration with IQAC-CSIC and UC Davis — homes to a protein overexpressed after acute traumatic brain injury and reduces lesion size, inflammation, and cell death in mouse and pig models. An IND filing is planned. Stories here cover both threads. See #glp-1 and #alzheimers for adjacent coverage.
Researchers at China Pharmaceutical University reported in Advanced Functional Materials on October 22, 2026 a leucine zipper-inspired peptide that binds the protein VHL, packed into a lipid nanocomplex carrying the T7 targeting peptide so that it reaches dopamine-producing neurons and their mitochondria. Given systemically, the complex reached those neurons within two hours, released the peptide in acidic conditions, and disrupted VHL's interaction with DVL-2, raising β-catenin and hexokinase 2 and improving mitochondrial energy production. Treatment reduced neurodegeneration and motor and coordination deficits in both an MPTP toxin model and an α-synuclein overexpression model; the work is preclinical.
Researchers at the University of Rouen Normandy and Inserm reported in Frontiers in Pharmacology on October 21, 2026 that a single 10-nanogram injection into the brain's ventricles of OP, an analog of octadecaneuropeptide (ODN), a peptide made by astrocytes, prevented the loss of dopamine-producing neurons in mice given the toxin MPTP. The peptide reduced oxidative damage, lowered the inflammatory marker TNF-α while raising IL-10, and preserved tight-junction proteins of the blood-brain barrier, assessed seven days after the toxin. The work is in an acute mouse model, and the peptide was delivered directly into the brain.
Aivocode is preparing first-in-human Phase 1 dosing for its CAQK tetrapeptide candidate in acute traumatic brain injury, building on the December 2025 EMBO Molecular Medicine paper that established the neuroprotective mechanism in rodent models. CAQK is a four-amino-acid peptide (Cys-Ala-Gln-Lys) that homes specifically to brain extracellular matrix exposed by tissue damage, enabling targeted delivery of therapeutic payloads to injured but not healthy brain regions. The preclinical data showed reduced lesion volume and improved functional recovery in mouse and rat TBI models when CAQK was conjugated to neuroprotective small molecules. The Phase 1 program — IND-enabling work ongoing — would represent one of the few peptide-based TBI candidates entering clinical testing, an indication with no FDA-approved neuroprotective therapies.
An IQAC-CSIC, UC Davis, and Aivocode collaboration published in EMBO Molecular Medicine demonstrates that the four-amino-acid peptide CAQK, given intravenously after acute traumatic brain injury, homes specifically to a protein overexpressed in injured brain tissue and reduces lesion size, inflammation, and cell death. In mouse and pig TBI models, CAQK-treated animals showed lower expression of inflammatory markers and improved memory and behavioral test outcomes versus untreated controls, with no overt toxicity. Aivocode — a Sanford Burnham Prebys spin-out — has signaled it will seek FDA authorization to begin Phase 1 human trials. The work targets a market with no approved drug for stopping secondary TBI damage; Spain alone records about 100,000 TBIs annually.
A living systematic review presented at the American Academy of Neurology 2026 Annual Meeting integrating Phase 2/3 trials and real-world data from 2+ million individuals with diabetes found GLP-1 receptor agonist use was associated with a 20-35% lower incidence of dementia versus DPP-4 or SGLT2 inhibitors. Effect was strongest for semaglutide, despite the EVOKE Phase 3 Alzheimer's trial missing its cognitive endpoint.
A comprehensive NeurologyLive review details emerging evidence for GLP-1 receptor agonists across neurological diseases including Alzheimer's, Parkinson's, multiple sclerosis, and stroke. Despite setbacks in the Phase 3 EVOKE Alzheimer's trial, ongoing trials like LIGHT-MCI and OxSENSE continue to explore neurobiological mechanisms beyond metabolic effects.